Figure 2. Changes in Bone Mineral Density (BMD) in the First Year of the Trial.

A, Compared with the positive control (group A), a significant difference in the percentage change in BMD after sequential therapy was observed in the lumbar spine for the zoledronate treatment group (group ZOL, which combines groups B, C, and D). B and C, No significant difference in the percentage change in BMD was observed for the total hip or femoral neck. D, Subgroup analysis suggested that the significant difference was associated with the duration of denosumab treatment before enrollment. A significant difference was only observed in the subgroup with 3 or more years of denosumab treatment before enrollment compared with group A and the ZOL subgroup with less than 3 years of treatment. Horizontal lines and boxes represent the median and IQR percentage changes in BMD, respectively; error bars represent 95% CIs.